Tags: Drug.
Palbociclib (also known as compound number PD-0332991) is an experimental drug for the treatment of breast cancer being developed by Pfizer.In a phase 2 trial reported at the April 2014 annual meeting of the American Association for Cancer Research palbociclib was shown to significantly slow the progression of advanced cancer but was not shown to have a statistically significant effect on increasing patients’ overall survival times.It is a selective inhibitor of the cyclin-dependent kinases CDK4 and CDK6.
